Akcea Therapeutics Inc. (NASDAQ: AKCA) and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) were each crushed on Tuesday after each announced that it received a Complete Response Letter (CRL) from U.S. Food and Drug Administration (FDA).
Specifically, this letter comes from the FDA’s Division of Metabolism and Endocrinology Products in regards to the New Drug Application (NDA) for Waylivra (volanesorsen).
For some quick background: Waylivra is also under regulatory review in the European Union and Canada for the treatment of people with familial chylomicronemia syndrome (FCS).
FCS is an ultra-rare, devastating hereditary disease that causes unpredictable and potentially fatal acute pancreatitis, as well as chronic complications due to permanent organ damage, and has a severe impact on daily living.
Paula Soteropoulos, CEO of Akcea, commented:
We are extremely disappointed with the FDA’s decision. FCS is an ultra-rare and debilitating disease. Our disappointment extends to the patient and physician community who currently do not have a treatment available to them. We continue to feel strongly that WAYLIVRA demonstrates a favorable benefit/risk profile in people with FCS as was reflected in the positive outcome from our Advisory Committee hearing in May. We will continue to work with the FDA to confirm the path forward.
Shares of Akcea were last seen down about 26% at $24.48, with a consensus analyst price target of $39.00 and a 52-week trading range of $15.20 to $40.75.
Ionis shares were down 15% at $45.65. The consensus price target is $58.64 and the 52-week range is $39.07 to $65.51.
100 Million Americans Are Missing This Crucial Retirement Tool
The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.
Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.
A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.
Click here to learn how to get a quote in just a few minutes.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
